Anticoagulant – edoxaban tosilate

There are several points along the clotting cascade that could be targets for anticoagulants.Edoxaban is being developed by Daiichi Sankyo, and is showing promise in clinical trials.

Classical anticoagulants like warfarin and heparin have their problems: there are issues with dosing, interactions with other drugs and even foodstuffs, and it can be a challenge to maintain effective, safe blood thinning when required.

This is a particular issue with deep vein thrombosis prophylaxis during surgery, and clots that can lead to stroke are also common in patients with atrial fibrillation. So better, safer, more predictable anticoagulants would be of great benefit.

There are several points along the clotting cascade that could be targets for anticoagulants. One drug that acts as an inhibitor of Factor Xa, the serine protease that converts prothrombin to thrombin, has already been approved – Bayer’s rivaroxaban. Another, edoxaban, is being developed by Daiichi Sankyo, and is showing promise in clinical trials.¹

In one single blind, placebo-controlled, randomised, two-part study, 85 healthy subjects were given single ascending